

NexGard
SPECTRA®



TAKE PARASITE PROTECTION TO THE **NEXT LEVEL**

One-And-Done monthly parasite protection* dogs love

9 out of 10 dogs prefer NexGard SPECTRA®^{1,2}**



Fleas



Ticks



Mites



Lungworm



Roundworm



Boehringer
Ingelheim

WHAT DO OWNERS AND PRACTICES NEED FROM PARASITE PROTECTION?

Canine parasite protection is an important part of your practice and a vital health service to dogs, owners and the local community, so you need to choose a product that delivers:

For owners:

- Easy-to-give convenience
- Broad-spectrum efficacy***
- Demonstrated palatability

For practices:

- Support for risk-based prescribing
- Ease of compliance
- Simplified stock control

PARASITE PROTECTION COULDN'T BE EASIER

One monthly, tasty chew provides parasite cover against key parasites:*

MILBEMYCIN OXIME

 Controls roundworm

 Prevents lungworm disease

AFOXOLANER

 Eliminates ear mites

 Kills fleas

 Terminates ticks

 Manages mites†

ALSO COVERS

 Hookworm

 Whipworm

 Heartworm

 Eyeworm

†The mite indication for NexGard SPECTRA® is for treatment of sarcoptic mange, demodicosis and *Otodectes cynotis*.

NEXGARD SPECTRA®



ELIMINATES FLEAS

- › The No.1 parasite concern for pet owners³
- › Challenging to control due to their life cycle
- › Only 5% of fleas are seen; 95% are in immature stages (eggs, larvae, pupae) in the environment⁴



The afoxolaner effect†:

- › Fleas start dying after just 2 hours⁵
- › All fleas are dead within 6 hours⁵
- › Kills fleas before they can lay eggs⁶




TERMINATES TICKS

- › 1 in 3 dogs in the UK are infested with ticks⁷
- › 1 in 50 ticks carry Lyme disease,⁸ transmitted by *Ixodes* spp.
- › Babesiosis has been diagnosed in untravelling UK dogs^{9,10}

THEY ARE HARD TO SPOT >>

The afoxolaner effect†:

- › Kills ticks within 24 hours¹¹
- › Kills ticks before the transmission window for Lyme disease and babesiosis^{12,13}



NexGard SPECTRA® is effective against several tick species, including *Ixodes ricinus*, *Ixodes hexagonus*, *Rhipicephalus sanguineus*, *Hyalomma marginatum* and *Dermacentor reticulatus*, which account for over 99% of ticks found on dogs in the UK.⁷

NEXGARD SPECTRA®



PREVENTS LUNGWORM DISEASE

- › *Angiostrongylus vasorum* is spreading through the UK and Ireland^{14,15}
- › 99% of UK vets report being asked by pet owners about lungworm¹⁶
- › Lungworm disease in dogs is serious and can be fatal – monthly prevention is better than cure

**You don't want to wait
until you see sick dogs**

Professor Eric Morgan, MA VetMB PhD DipEVPC MRCVS.

- › Monthly administration of NexGard SPECTRA® ensures that lungworm is always targeted within the pre-patent period, before they begin to shed eggs into the environment^{17,18}
- › 99.9% reduction of larval shedding¹⁷
- › 94.9% reduction of lungworm burden¹⁷




CONTROLS ROUNDWORM


- › Roundworm eggs can live in the environment for years and pose a zoonotic risk¹⁹
- › 1 in 5 dogs have *Toxocara* spp. eggs on their paws and coats²⁰

- › WormWatch®, a recent study supported by Boehringer Ingelheim alongside leading parasitologists, revealed **86.6%** of 142 parks in the UK and Ireland tested positive for *Toxocara* spp. eggs²¹
- › Monthly worming is the most effective way to eliminate eggs shedding into the environment

INCUBATION PERIOD - ADULT WORM DEVELOPMENT



Efficacy of NexGard SPECTRA® in dogs naturally infested with *T. canis*²²



NEXGARD SPECTRA®



MANAGES MITES

- › Mites are contagious, zoonotic, and can be highly pruritic
- › NexGard SPECTRA® treats skin infestations caused by three different types of mite:

EAR MITE INFESTATIONS

- › 98.5–100% efficacy after 1 month^{23,24}

DEMODICOSIS




- › 98–100% efficacy after 3 monthly treatments^{26,27}

SARCOPTIC MANGE



- › 100% efficacy after 2 monthly treatments²⁵



NEXGARD SPECTRA® IS IDEAL FOR PUPPIES

- › Can be started from just 8 weeks of age, and from 1.35 kg
- › Five weight ranges enable appropriate monthly dosing as puppies grow
- › Monthly dosing follows ESCCAP puppy roundworming guidelines⁹
- › Suitable for breeding, pregnant and lactating bitches^{††}

EASY, BROAD- SPECTRUM PROTECTION

- › Easy-to-give, tasty chew
- › Simple monthly intervals
- › Can be given with or without food
- › Confidence the entire dose has been received
- › Immediate handling
- › No restrictions on shampooing or swimming



*Terms and conditions apply (available on request)

HOW DOES NEXGARD SPECTRA® COMPARE?

» 9 out of 10 dogs prefer NexGard SPECTRA®^{1,2**}

	NexGard SPECTRA®	Advocate®	Credelio™ Plus	Simparica TRIO™	Bravecto® TriUNO
Palatable	✓	Spot on	✓ ^{**}	✓ ^{**}	✗
Licensed for pregnancy/lactation	✓	✗	✗ ^{††}	✗	✗
Can be given on an empty stomach ^{††}	✓	Spot on	✗	✓	✗
Fleas	✓	✓	✓	✓	✓
Ticks	✓	✗	✓	✓	✓
Mites including ear mites	✓	✓	✗ ^{§§}	✗ ^{§§}	✗
Roundworm	✓	✓	✓	✓	✓
Lungworm	✓	✓	✓	✓	✓

VS. SIMPARICA TRIO™



VS. CREDELIO™ PLUS



The table shows activity against fleas, ticks, roundworm, lungworm and mites. Some of the products listed have claims against other parasites. Refer to the Summary of Product Characteristics for each product for full details of the licensed indications.

^{**} 9 out of 10 dogs that demonstrated a preference in the studies preferred NexGard SPECTRA®.

^{††} Credelio™ Plus – the safety of the product has not been established during pregnancy, lactation or in breeding dogs; use only according to benefit-risk assessment by the responsible veterinarian.

^{††} Where SPC advises to give with/shortly after food, this is recorded here as X.

^{§§} Credelio™ Plus is licensed to treat demodicosis but not sarcoptic mange or ear mites. Simparica TRIO™ is licensed to treat demodicosis and sarcoptic mange, but not ear mites.

NEXGARD SPECTRA® IS AN EASY-TO-GIVE, MONTHLY, TASTY CHEW



Extra-small
1.35 kg – 3.5 kg



Small
> 3.5 kg – 7.5 kg



Medium
> 7.5 kg – 15 kg



Large
> 15 kg – 30 kg



Extra-large
> 30 kg – 60 kg



BENEFITS FOR YOUR PRACTICE



Fits with health plans



Flea advice service



Comprehensive training and switching support



Webinars, short videos and more available on the Boehringer Academy

Support for risk-based prescribing with Parassess®, the expert-led online risk assessment tool based on ESCCAP guidelines



Learn more about Parassess®

REFERENCES

1. Perier N, Carithers DS, Everett WR, et al. Preference of Dogs between Two Oral Formulations of Endectoparasiticides: NexGard SPECTRA® (Afoxolaner and Milbemycin Oxime) and Simparica Trio™ (Sarolaner, Moxidectin and Pyrantel). *Open Journal of Veterinary Medicine*. 2020;10:155–16.
2. Perier N, Carithers DS, Everett WR, et al. Preference in Dogs of Two Oral Endectoparasiticide Formulations: NexGard Spectra® (Afoxolaner and Milbemycin Oxime) and Credelio® Plus (Lotilaner and Milbemycin Oxime). *Open Journal of Veterinary Medicine*. 2021; 11:289–298.
3. Ipsos. Usage & Attitudes Report for Merial Europe. 2015.
4. Halos L, Beugnet F, Cardosos L, et al. Flea control failure? Myths and realities. *Trends Parasitol*. 2014;30(5):228–233.
5. Beugnet F, deVos C, Liebenberg J, et al. Afoxolaner against fleas: immediate efficacy and resultant mortality after short exposure on dogs. *Parasite*. 2014;21:42.
6. EMA. European Public Assessment Report (EPAR): NexGard Spectra chewable tablets for dogs (afoxolaner and milbemycin oxime). European Medicines Agency, London.
7. Abdullah S, Helps C, Tasker S, et al. Ticks infesting domestic dogs in the UK: a large-scale surveillance programme. *Parasit Vectors*. 2016;9:391.
8. Abdullah S, Helps C, Tasker S, et al. Prevalence and distribution of Borrelia and Babesia species in ticks feeding on dogs in the UK. *Med Vet Entomol*. 2018;32:14–22.
9. Phipps LP, Del Mar Fernandez De Marco M, Hernandez-Triana LM, et al. Babesia canis detected in dogs and associated ticks from Essex. *Vet Rec*. 2016;178:243–244.
10. Swainsbury C, Bengtson G, Hill P. Babesiosis in dogs. *Vet Rec*. 2016;178:172.
11. Halos L, Lebon W, Chalvet-Monfray K, et al. Immediate efficacy and persistent speed of kill of a novel oral formulation of afoxolaner (NexGard™) against induced infestations with Ixodes ricinus ticks. *Parasit Vectors*. 2014;7:452.
12. Wright I. What do dog owners need from tick protection? *Vet Times*. 2018;48:10–11.
13. Beugnet F, Halos L, Guillot J. Textbook of Clinical Parasitology in dogs and cats. Servet editorial – Grupo Asís Biomedica, S.L.. 2018.
14. Taylor CS, Garcia Gato R, Learmount J, et al. Increased prevalence and geographic spread of the cardiopulmonary nematode Angiostrongylus vasorum in fox populations in Great Britain. *Parasitology*. 2015;142:1190–1195.
15. McCarthy G, Ferrand M, De Waal T, et al. Geographical distribution of Angiostrongylus vasorum in foxes (Vulpes vulpes) in the Republic of Ireland. *Parasitology*. 2016;143:588–593.
16. Elanco. Survey data shows dog owners don't know the risks of lungworm. Improve Veterinary Practice, 2023. Available online at: <https://www.veterinary-practice.com/2023/survey-data-shows-dog-owners-dont-know-the-risks-of-lungworm>. Accessed 18 December 2025.
17. Lebon W, Tieleman E, Rehbein S, et al. Monthly administrations of milbemycin oxime plus afoxolaner chewable tablets to prevent Angiostrongylus vasorum infection in dogs. *Parasit Vectors*. 2016;9:485.
18. EMA. European Public Assessment Report (EPAR): NexGard SPECTRA® chewable tablets for dogs (afoxolaner and milbemycin oxime). European Medicines Agency, London.
19. ESCCAP. Worm Control in Dogs and Cats. ESCCAP Guideline 01 Seventh Edition, June 2025.
20. Panova OA, Khrustalev AV. Dog walking brings Toxocara eggs to people's homes. *Vet Parasitol*. 2018;262:16–19.
21. Airs PM, Brown C, Gardiner E, Maciag L, Adams JP, Morgan ER. WormWatch: Park soil surveillance reveals extensive Toxocara contamination across the UK and Ireland. *Vet Rec*. 2023 Jan;192(1).
22. Rehbein S, Knaus M, Mallouk Y, et al. Efficacy against nematode infections and safety of afoxolaner plus milbemycin oxime chewable tablets in domestic dogs under field conditions in Europe. *Parasitol Res*. 2017;116:259–269.
23. Carithers et al. Assessment of afoxolaner efficacy against Otodectes cynotis infestations of dogs. *Parasit Vectors*. 2016;9:635. (Open Access).
24. Panarese et al. Efficacy of afoxolaner for the treatment of ear mite infestation under field conditions. *Vet Parasitol*. 2021;300.
25. Hampel V, Knaus M, Schafer J, et al. Treatment of canine sarcoptic mange with afoxolaner (NexGard SPECTRA®) and afoxolaner plus milbemycin oxime (NexGard®) chewable tablets: efficacy under field conditions in Portugal and Germany. *Parasite*. 2018;25:63.
26. Rehbein S, de Vos C, Beugnet FC, et al. Efficacy of Once-Monthly Doses of Oral Afoxolaner and Afoxolaner/Milbemycin Oxime in a Well-Controlled Study for the Treatment of Canine Generalized Demodicosis. *Open J Vet Med*. 2018;08:250–265.
27. Lebon W, Beccati M, Bourdeau P, et al. Efficacy of two formulations of afoxolaner (NexGard®) and (NexGard Spectra®) for the treatment of generalised demodicosis in dogs, in veterinary dermatology referral centers in Europe. *Parasit Vectors*. 2018;11:506.



NexGard SPECTRA®



Scan the QR code
to learn more about
NexGard SPECTRA®

*NexGard SPECTRA® is indicated for the treatment of flea and tick infestations in dogs when the concurrent prevention of heartworm disease, angiostrongylosis and/or treatment of gastrointestinal nematode infestations is indicated. NexGard SPECTRA®'s mite indication is for treatment of sarcoptic mange, ear mites due to *Otodectes cynotis* and demodicosis.

**9 out of 10 dogs that demonstrated a preference in the studies preferred NexGard SPECTRA®.

***As required by individual dogs.

†Data from NexGard® studies.

††The safety of the veterinary medicinal product has not been established in breeding males. In breeding males, use only according to the benefit-risk assessment by the responsible veterinarian.

NexGard SPECTRA® contains afoxolaner and milbemycin oxime. UK: POM-V IE: POM. Further information available in the SPC or from Boehringer Ingelheim Animal Health UK Ltd., RG12 8YS, UK. UK Tel: 01344 746959 (sales) or 01344 746957 (technical). IE Tel: 01 291 3985 (all queries). Email: vetenquiries@boehringer-ingelheim.com. NexGard SPECTRA® is a registered trademark of Boehringer Ingelheim Animal Health France SCS, used under licence. ©2026 Boehringer Ingelheim Animal Health UK Ltd. All rights reserved. Date of preparation: Jan 2026. UI-PET-0017-2026. Use Medicines Responsibly. Prescription decisions are for the person issuing the prescription alone.



Boehringer
Ingelheim